Previous Close | 0.9900 |
Open | 0.9900 |
Bid | 0.9477 x 1800 |
Ask | 1.0000 x 1100 |
Day's Range | 0.9600 - 0.9900 |
52 Week Range | 0.7400 - 1.4100 |
Volume | |
Avg. Volume | 217,170 |
Market Cap | 41.222M |
Beta (5Y Monthly) | 1.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2200 |
Earnings Date | Jan 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for RPID
Company to give technical presentation on its innovative Growth Direct® Rapid Sterility ApplicationLOWELL, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will exhibit at the 2024 Parenteral Drug Association (“PDA”) Annual Meeting from M
LOWELL, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the virtual KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to p
LOWELL, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that, effective March 4, 2024, the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 150,000 shares of the Company’s Class A common